Skip to content

Prime Medicine PRME Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
Beam Therapeutics logo
Beam TherapeuticsBEAM
Regenxbio logo
RegenxbioRGNX
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's deferred tax assets and other non-current assets?
Prime Medicine (PRME) reported deferred tax assets and other non-current assets of $1M in Q1 2026.
What is the long-term trend for Prime Medicine's deferred tax assets and other non-current assets?
Over 4 years (2021 to 2025), Prime Medicine's deferred tax assets and other non-current assets has grown at a -20.3% compound annual growth rate (CAGR), from $2.47M to $1M.